FRANKFURT--The following is a summary of analysts' forecasts for Novartis AG (NVS) fourth-quarter results, based on a poll of nine analysts conducted by Dow Jones Newswires (figures in million dollars, EPS in dollar, DPS and target price in francs, according to IFRS). Earnings figures are scheduled to be released January 27.

=== 
              Net sales: 
 
4th Quarter       -total -Pharma  -Diovan -Gleevec -Lucentis 
AVERAGE           14,678   7,864      354    1,185       627 
Prev. Year        14,926   8,323      843    1,227       630 
+/- in %            -1.7    -5.5      -58     -3.5      -0.5 
 
MEDIAN            14,564   7,894      365    1,170       625 
Maximum           15,261   8,151      395    1,264       660 
Minimum           14,259   7,503      290    1,089       594 
Amount                 8       9        8        8         7 
 
Barclays              --   7,894      360    1,165       594 
Cowen and Company 14,575   7,870      325    1,210       660 
Deutsche Bank     14,878   8,025      387    1,174       625 
Exane BNP Paribas 14,991   8,151       --    1,262       614 
J.P. Morgan       14,449   7,906      395       --        -- 
Jefferies         14,462   7,687      369    1,089       609 
Morgan Stanley    14,552   7,756      290    1,162       630 
UBS               14,259   7,503      330    1,151        -- 
Zuercher KB       15,261   7,987      379    1,264       655 
 
 
                    Core      Core          Core 
               Operating       Net   Net attrib.     Core 
4th Quarter       income    income        profit      EPS 
AVERAGE            3,322     2,829         2,843     1.18 
Prev. Year         3,293     2,892         2,863     1.18 
+/- in %            +0.9      -2.2          -0.7     -0.3 
 
MEDIAN             3,275     2,809         2,810     1.18 
Maximum            3,538     2,878         2,976     1.23 
Minimum            3,140     2,794         2,778     1.13 
Amount                 9         5             4        9 
 
Barclays           3,140        --            --     1.14 
Cowen and Company  3,231     2,858         2,841     1.18 
Deutsche Bank      3,538        --         2,976     1.22 
Exane BNP Paribas  3,458        --            --     1.21 
J.P. Morgan        3,275     2,878            --     1.18 
Jefferies          3,222     2,794            --     1.15 
Morgan Stanley     3,404        --            --     1.23 
UBS                3,240     2,809         2,778     1.15 
Zuercher KB        3,388     2,807         2,778     1.13 
 
 
                 Target price  Rating               DPS 2014 
 
AVERAGE                 96.42  positive 6   AVERAGE     2.59 
Prev. Quarter           91.67  neutral  3   Prev. Year  2.45 
+/- in %                 +5.2  negative 0   +/- in %    +5.7 
 
MEDIAN                  95.75               MEDIAN      2.62 
Maximum                112.00               Maximum     2.65 
Minimum                 85.00               Minimum     2.50 
Amount                      6               Amount         3 
 
Barclays                88.00  Equalweight                -- 
Cowen and Company          --  Outperform                 -- 
Deutsche Bank           95.50  Hold                       -- 
Exane BNP Paribas       96.00  Outperform               2.65 
J.P. Morgan                --  Overweight                 -- 
Jefferies              112.00  Buy                        -- 
Morgan Stanley          85.00  Equalweight                -- 
UBS                    102.00  Buy                      2.62 
Zuercher Kantonalbank      --  Overweight               2.50 
=== 

Year-earlier figures are as restated by the company.

DJG/voi 

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novartis Charts.